|
|
||||||||||
|
J Am Coll Cardiol, 2007; 50:1373-1380, doi:10.1016/j.jacc.2007.06.047
(Published online 20 August 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||







* Deutsches Herzzentrum, Technische Universität, Munich, Germany
Department of Cardiology, University Hospital Bern, Bern, Switzerland
Reina Sofia Hospital, University of Córdoba, Córdoba, Spain
University of Basel, Basel, Switzerland
|| Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
¶ Cardiovascular Center in Chungnam National University Hospital, Daejeon, Korea
# A.O.R.N. "S. G. Moscati," Avellino, Italy
** Department of Social and Preventive Medicine, University Hospital Bern, Bern, Switzerland

Service of Cardiology, Clinique Cecil, Lausanne, Switzerland.
Manuscript received May 31, 2007; revised manuscript received June 15, 2007, accepted June 26, 2007.
* Reprint requests and correspondence: Dr. Albert Schömig, Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany. (Email: aschoemig{at}dhm.mhn.de).
Objectives: Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drug-eluting stents (DES)—sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)—in patients with coronary artery disease.
Background: It is not known whether there are differences in late outcomes between the 2 most commonly used DES: SES and PES.
Methods: Sixteen randomized trials of SES versus PES with a total number of 8,695 patients were included in this meta-analysis. A full set of individual outcome data from 5,562 patients was also available. Mean follow-up period ranged from 9 to 37 months. The primary efficacy end point was the need for reintervention (target lesion revascularization). The primary safety end point was stent thrombosis. Secondary end points were death and recurrent myocardial infarction (MI).
Results: No significant heterogeneity was found across trials. Compared with PES, SES significantly reduced the risk of reintervention (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.63 to 0.87, p < 0.001) and stent thrombosis (HR 0.66; 95% CI 0.46 to 0.94, p = 0.02) without significantly impacting on the risk of death (HR 0.92; 95% CI 0.74 to 1.13, p = 0.43) or MI (HR 0.84; 95% CI 0.69 to 1.03, p = 0.10).
Conclusions: Sirolimus-eluting stents are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend toward a higher risk of MI with PES, especially after the first year from the procedure.
| ||||||||
Related Article
J. Am. Coll. Cardiol. 2007 50: 1381-1385.
This article has been cited by other articles:
![]() |
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al. A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus J. Am. Coll. Cardiol., August 26, 2008; 52(9): 727 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur. Heart J., August 2, 2008; 29(16): 1975 - 1982. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takano, M. Yamamoto, D. Murakami, S. Inami, K. Okamatsu, K. Seimiya, T. Ohba, Y. Seino, and K. Mizuno Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents Circ Cardiovasc Intervent, August 1, 2008; 1(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF] |
||||
![]() |
A. M. Galloe, L. Thuesen, H. Kelbaek, P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamaki, A. Junker, J. Aaroe, et al. Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial JAMA, January 30, 2008; 299(4): 409 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mukherjee and D. J. Moliterno Effectiveness of Drug-Eluting Stents in Real-World Patients JAMA, January 30, 2008; 299(4): 454 - 455. [Full Text] [PDF] |
||||
![]() |
Sirolimus-Eluting vs. Paclitaxel-Eluting Stents: A Meta-Analysis Journal Watch Cardiology, October 3, 2007; 2007(1003): 3 - 3. [Full Text] |
||||
![]() |
D. J. Kereiakes The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1381 - 1385. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |